Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia.
Zeng AGX, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, Chan-Seng-Yue M, Voisin V, van Galen P, Tierens A, Cheok M, Preudhomme C, Dombret H, Daver N, Futreal PA, Minden MD, Kennedy JA, Wang JCY, Dick JE. Zeng AGX, et al. Among authors: tierens a. Nat Med. 2022 Jun;28(6):1212-1223. doi: 10.1038/s41591-022-01819-x. Epub 2022 May 26. Nat Med. 2022. PMID: 35618837
Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease.
Tierens A, Arad-Cohen N, Cheuk D, De Moerloose B, Fernandez Navarro JM, Hasle H, Jahnukainen K, Juul-Dam KL, Kaspers G, Kovalova Z, Lausen B, Norén-Nyström U, Palle J, Pasauliene R, Jan Pronk C, Saks K, Zeller B, Abrahamsson J. Tierens A, et al. J Clin Oncol. 2024 Apr 11:JCO2301841. doi: 10.1200/JCO.23.01841. Online ahead of print. J Clin Oncol. 2024. PMID: 38603646
Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression.
Luciani GM, Xie L, Dilworth D, Tierens A, Moskovitz Y, Murison A, Szewczyk MM, Mitchell A, Lupien M, Shlush L, Dick JE, Arrowsmith CH, Barsyte-Lovejoy D, Minden MD. Luciani GM, et al. Among authors: tierens a. Exp Hematol. 2019 Jan;69:27-36. doi: 10.1016/j.exphem.2018.10.006. Epub 2018 Oct 22. Exp Hematol. 2019. PMID: 30352278 Free article.
Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.
Murphy T, Zou J, Daher-Reyes GS, Arruda A, Gupta V, McNamara CJ, Minden MD, Schimmer AD, Sibai H, Yee KWL, Korulla M, Stockley T, Kamel-Reid S, Maze D, Tierens A, Bratman SV, Schuh AC, Chan SM. Murphy T, et al. Among authors: tierens a. Blood Adv. 2019 Aug 13;3(15):2307-2311. doi: 10.1182/bloodadvances.2019000306. Blood Adv. 2019. PMID: 31371380 Free PMC article.
Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort.
England JT, McNamara CJ, Kennedy JA, Capo-Chichi JM, Huang J, Arruda A, Nye T, Cheung V, Claudio JO, Maze D, Sibai H, Tierens A, Tsui H, Bankar A, Xu W, Stockley T, Gupta V. England JT, et al. Among authors: tierens a. Leukemia. 2022 Jun;36(6):1689-1692. doi: 10.1038/s41375-022-01544-x. Epub 2022 Mar 26. Leukemia. 2022. PMID: 35347238 Free PMC article. No abstract available.
100 results